APC
BMRN icon

Aspire Private Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aspire Private Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50
Closed -$4K – 607
2021
Q4 		$4K Hold
50
– – ﹤0.01% 443
2021
Q3 		$4K Hold
50
– – ﹤0.01% 400
2021
Q2 		$4K Buy
+50
New +$3.96K ﹤0.01% 412

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Aspire Private Capital's BMRN Position: Q1 2022 in Review

Aspire Private Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 50 shares — an estimated $4K sold.

Aspire Private Capital first reported a position in BMRN in Q2 2021 and held it in 3 quarters. The position peaked at $4K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Aspire Private Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Aspire Private Capital sold 50 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $4K.
  • Aspire Private Capital first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Aspire Private Capital's BioMarin Pharmaceuticals position peaked at $4K in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Aspire Private Capital's 13F filing for Q1 2022, filed 10 May 2022.